Takeda Pharmaceutical Company Limited (TKPHF) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Tokyo, Japan. Le PDG actuel est Christophe Weber.
TKPHF a date d'introduction en bourse 2008-06-25, 49,281 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $54.53B.
Takeda Pharmaceutical Company Limited is a global pharmaceutical company headquartered in Tokyo, Japan, with operations across Japan, the United States, Europe, and other international markets. Founded in 1781, the company engages in the research, development, manufacture, and marketing of pharmaceutical products across five core therapeutic areas: gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Takeda markets numerous branded pharmaceutical products including Entyvio, Velcade, Adcetris, and Takhzyro, among others, and maintains an extensive network of collaborations, licensing agreements, and strategic alliances with leading research institutions and biotechnology companies worldwide to support its innovation pipeline.
